E7050 Suppresses the Growth of Multidrug-Resistant Human Uterine Sarcoma by Inhibiting Angiogenesis via Targeting of VEGFR2-Mediated Signaling Pathways
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24119606 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Tsung-Teng Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan. Hauptthemen laut MEDLINE: Sarcoma, Signal Transduction, Vascular Endothelial Growth Factor Receptor-2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chang Gung Memorial Hospital, Ministry of Science and Technology of Taiwan, Chang Gung Memorial Hospital, Taiwan.
Abstract (Originalsprache)
E7050 is an inhibitor of VEGFR2 with anti-tumor activity; however, its therapeutic mechanism remains incompletely understood. In the present study, we aim to evaluate the anti-angiogenic activity of E7050 in vitro and in vivo and define the underlying molecular mechanism. It was observed that treatment with E7050 markedly inhibited proliferation, migration, and capillary-like tube formation in cultured human umbilical vein endothelial cells (HUVECs). E7050 exposure in the chick embryo chorioallantoic membrane (CAM) also reduced the amount of neovessel formation in chick embryos. To understand the molecular basis, E7050 was found to suppress the phosphorylation of VEGFR2 and its downstream signaling pathway components, including PLCγ1, FAK, Src, Akt, JNK, and p38 MAPK in VEGF-stimulated HUVECs. Moreover, E7050 suppressed the phosphorylation of VEGFR2, FAK, Src, Akt, JNK, and p38 MAPK in HUVECs exposed to MES-SA/Dx5 cells-derived conditioned medium (CM). The multidrug-resistant human uterine sarcoma xenograft study revealed that E7050 significantly attenuated the growth of MES-SA/Dx5 tumor xenografts, which was associated with inhibition of tumor angiogenesis. E7050 treatment also decreased the expression of CD31 and p-VEGFR2 in MES-SA/Dx5 tumor tissue sections in comparison with the vehicle control. Collectively, E7050 may serve as a potential agent for the treatment of cancer and angiogenesis-related disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan.
- Traditional Herbal Medicine Research Center, Taipei Medical University Hospital, Taipei 11031, Taiwan.
- Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.
- Graduate Institute of Biomedical Sciences, Division of Biotechnology, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.
- Department of Life Sciences, Agricultural Biotechnology Center, National Chung Hsing University, Taichung 40227, Taiwan.
- The iEGG and Animal Biotechnology Center and the Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung 40227, Taiwan.
ORCID-Profile: Chuan-Mu Chen, Song-Shu Lin, Tse-Hung Huang, Kowit-Yu Chong
Förderung
- Chang Gung Memorial Hospital
- Ministry of Science and Technology of Taiwan
- Chang Gung Memorial Hospital, Taiwan
- the Chang Gung University, Taiwan
- iEGG and Animal Biotechnology Center from the Feature Areas Research Center Program
- Higher Education Sprout Project by the Ministry of Education in Taiwan
Zitieren
APA
Huang, T. T., Chen, C. M., Lin, S. S., Lan, Y. W., Cheng, H. C., Choo, K. B., Wang, C. C., Huang, T. H., & Chong, K. Y. (2023). E7050 Suppresses the Growth of Multidrug-Resistant Human Uterine Sarcoma by Inhibiting Angiogenesis via Targeting of VEGFR2-Mediated Signaling Pathways. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24119606
Vancouver
Huang TT, Chen CM, Lin SS, Lan YW, Cheng HC, Choo KB, et al. E7050 Suppresses the Growth of Multidrug-Resistant Human Uterine Sarcoma by Inhibiting Angiogenesis via Targeting of VEGFR2-Mediated Signaling Pathways. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24119606
BibTeX
@article{Huang2023,
author = {Huang, Tsung-Teng and Chen, Chuan-Mu and Lin, Song-Shu and Lan, Ying-Wei and Cheng, Hsu-Chen and Choo, Kong-Bung and Wang, Ching-Chiung and Huang, Tse-Hung and Chong, Kowit-Yu},
title = {E7050 Suppresses the Growth of Multidrug-Resistant Human Uterine Sarcoma by Inhibiting Angiogenesis via Targeting of VEGFR2-Mediated Signaling Pathways},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24119606}
}
EUVIMED